ArticleJournal of natural medicines2026
Hemp seed oil ameliorates DSS-induced ulcerative colitis in mice by altering transcriptomics and metabolomics.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease with complex pathogenesis and limited treatments. Hemp seed oil, with its unique ω-6/ω-3 polyunsaturated fatty acid ratio and phenolic antioxidants, exhibits anti-inflammatory and gut barrier-enhancing properties, though its mechanisms in UC are not fully understood. Here, we applied an integrated transcriptomics and metabolomics approach to investigate the effects of hemp seed oil in dextran sulfate sodium (DSS)-induced UC mice. Treatment with hemp seed oil (1 g/kg) significantly alleviated disease activity, suppressed proinflammatory cytokine levels (interleukin (IL)-6, IL-1β, and IL-17), and improved colonic histopathology. Metabolomic profiling via ultrahigh-performance liquid chromatography-quadrupole-orbitrap tandem mass spectrometry (UPLC-Q-Orbitrap MS/MS) identified 19 significantly altered colonic metabolites, predominantly involved in amino acid metabolism, energy homeostasis, and lipid signalling pathways. Transcriptomic analysis suggested that hemp seed oil treatment was associated with inhibition of the IL-17 and tumor necrosis factor (TNF) signalling pathways while upregulating genes involved in barrier function (e.g., zonula occludens-1 (ZO-1) and Occludin). Integrative analysis revealed strong inverse correlations between key metabolites (e.g., docosahexaenoic acid ethyl ester, adenosine diphosphate (ADP)) and IL-17 pathway activation (IL17A, C-X-C motif chemokine ligand 10 (CXCL10)), suggesting that hemp seed oil may attenuate UC through reprogramming the "metabolism‒inflammation" axis. These findings suggest potential multitarget therapeutic mechanisms of hemp seed oil against UC, indicate critical links between metabolic reprogramming and the immune‒inflammatory axis, and offer novel insights for the development of phytomedicine for the treatment of inflammatory bowel disease.
Indexed as
Identifiers
42766258What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.